You are required to be logged in to access the full website
Click here if you have forgotten your username or password
Therapy Areas
16 June 2026 - Innoviva Specialty Therapeutics, a subsidiary of Innoviva Inc (Nasdaq:INVA) focused on innovative therapies in critical care and infectious disease, said on Tuesday that it has entered into an exclusive distribution and licensing agree...
16 June 2026 - Minghui Pharmaceutical, a late-stage clinical biopharmaceutical company focused on developing innovative therapies for oncology and autoimmune diseases, announced on Monday the presentation of complete Phase I/II clinical data for MHB0...
16 June 2026 - Clinical-stage biotechnology company Kalohexis Inc announced on Monday that data supporting dual melanocortin-3 receptor/melanocortin-4 receptor (MC3R/MC4R) activation as a novel mechanism to drive healthier, more durable weight loss h...
16 June 2026 - Hillhurst Biopharmaceuticals Inc, a clinical-stage biopharmaceutical company focused on developing novel oral liquid drug products based on known inhaled therapeutics, announced on Monday that the first subject has been dosed in its Ph...
16 June 2026 - US biopharmaceutical company Antharis Therapeutics Inc and Lonza (SWX:LONN), a contract development and manufacturing organisation (CDMO) based in Switzerland, announced on Monday an exclusive, target-specific licensing agreement to de...
16 June 2026 - Clinical-stage biotechnology company Halia Therapeutics Inc announced on Monday that the US Food and Drug Administration (FDA) has granted Fast Track designation to ofirnoflast (HT-6184) for the treatment of adult patients with lower-r...
15 June 2026 - Inhibrx Biosciences Inc (Nasdaq: INBX) disclosed on Monday that it has received U.S. Food and Drug Administration acceptance of its Biologics License Application for ozekibart (INBRX-109) for the treatment of patients with unresectable...